|
Showing 1 - 3 of
3 matches in All Departments
This book contextualizes translational research and provides an up
to date progress report on therapies that are currently being
targeted in lung cancer. It is now well established that there is
tremendous heterogeneity among cancer cells both at the inter- and
intra-tumoral level. Further, a growing body of work highlights the
importance of targeted therapies and personalized medicine in
treating cancer patients. In contrast to conventional therapies
that are typically administered to the average patient regardless
of the patient's genotype, targeted therapies are tailored to
patients with specific traits. Nonetheless, such genetic changes
can be disease-specific and/or target specific; thus, the book
addresses these issues manifested in the somatically acquired
genetic changes of the targeted gene. Each chapter is written by a
leading medical oncologist who specializes in thoracic oncology and
is devoted to a particular target in a specific indication.
Contributors provide an in-depth review of the literature covering
the mechanisms underlying signaling, potential cross talk between
the target and downstream signaling, and potential emergence of
drug resistance.
This book contextualizes translational research and provides an up
to date progress report on therapies that are currently being
targeted in lung cancer. It is now well established that there is
tremendous heterogeneity among cancer cells both at the inter- and
intra-tumoral level. Further, a growing body of work highlights the
importance of targeted therapies and personalized medicine in
treating cancer patients. In contrast to conventional therapies
that are typically administered to the average patient regardless
of the patient's genotype, targeted therapies are tailored to
patients with specific traits. Nonetheless, such genetic changes
can be disease-specific and/or target specific; thus, the book
addresses these issues manifested in the somatically acquired
genetic changes of the targeted gene. Each chapter is written by a
leading medical oncologist who specializes in thoracic oncology and
is devoted to a particular target in a specific indication.
Contributors provide an in-depth review of the literature covering
the mechanisms underlying signaling, potential cross talk between
the target and downstream signaling, and potential emergence of
drug resistance.
|
|
Email address subscribed successfully.
A activation email has been sent to you.
Please click the link in that email to activate your subscription.